RU2269523C2 - Мускариновые агонисты - Google Patents

Мускариновые агонисты Download PDF

Info

Publication number
RU2269523C2
RU2269523C2 RU2002131937/04A RU2002131937A RU2269523C2 RU 2269523 C2 RU2269523 C2 RU 2269523C2 RU 2002131937/04 A RU2002131937/04 A RU 2002131937/04A RU 2002131937 A RU2002131937 A RU 2002131937A RU 2269523 C2 RU2269523 C2 RU 2269523C2
Authority
RU
Russia
Prior art keywords
butylpiperidin
propyl
ylpropyl
butylpiperidine
mmol
Prior art date
Application number
RU2002131937/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2002131937A (ru
Inventor
Карл-Магнус А. АНДЕРССОН (DK)
Карл-Магнус А. АНДЕРССОН
Бо Леннарт М. ФРИБЕРГ (US)
Бо Леннарт М. ФРИБЕРГ
Нильс СКЬЯЕРБАЕК (US)
Нильс СКЬЯЕРБАЕК
Трейси СПЭЛДИНГ (US)
Трейси СПЭЛДИНГ
Аллан К. ЮЛДЭМ (DK)
Аллан К. ЮЛДЭМ
Original Assignee
Акадиа Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акадиа Фармасьютикалз, Инк. filed Critical Акадиа Фармасьютикалз, Инк.
Publication of RU2002131937A publication Critical patent/RU2002131937A/ru
Application granted granted Critical
Publication of RU2269523C2 publication Critical patent/RU2269523C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2002131937/04A 2000-04-28 2001-04-27 Мускариновые агонисты RU2269523C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20079100P 2000-04-28 2000-04-28
US60/200,791 2000-04-28

Publications (2)

Publication Number Publication Date
RU2002131937A RU2002131937A (ru) 2004-06-20
RU2269523C2 true RU2269523C2 (ru) 2006-02-10

Family

ID=22743194

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002131937/04A RU2269523C2 (ru) 2000-04-28 2001-04-27 Мускариновые агонисты

Country Status (19)

Country Link
US (3) US6627645B2 (https=)
EP (1) EP1278741B1 (https=)
JP (2) JP4119126B2 (https=)
KR (2) KR20030005306A (https=)
CN (3) CN1814596A (https=)
AR (1) AR028385A1 (https=)
AT (1) ATE290000T1 (https=)
AU (2) AU2001259190B2 (https=)
BR (1) BR0110420A (https=)
CA (1) CA2407594A1 (https=)
DE (1) DE60109148T2 (https=)
ES (1) ES2238437T3 (https=)
MX (1) MXPA02010550A (https=)
NO (1) NO326106B1 (https=)
NZ (1) NZ521978A (https=)
RU (1) RU2269523C2 (https=)
TW (3) TWI310035B (https=)
WO (1) WO2001083472A1 (https=)
ZA (1) ZA200208504B (https=)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028385A1 (es) * 2000-04-28 2003-05-07 Acadia Pharm Inc Agonistas muscarinicos
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
BR0213611A (pt) 2001-10-02 2005-12-20 Acadia Pharm Inc Composto, composição farmacêutica, seus usos, método para aumentar a atividade de um receptor colinérgico, métodos para tratamento ou prevenção de distúrbio mental, dor, pressão intraocular aumentada e progressão ou formação de placas amilóides
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
ES2251624T3 (es) * 2001-12-28 2006-05-01 Acadia Pharmaceuticals Inc. Analogos de la tetrahidroquinolina como los agonistas muscarinicos.
CA2492305A1 (en) 2002-07-31 2004-02-05 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
JP2006515628A (ja) * 2003-01-23 2006-06-01 アカディア ファーマシューティカルズ，インコーポレーテッド ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
WO2004073639A2 (en) * 2003-02-19 2004-09-02 Merck & Co. Inc. Treatment of psychosis with a muscarinic m1 receptor ectopic activator
NZ542690A (en) * 2003-03-28 2009-04-30 Acadia Pharm Inc Muscarinic M1 receptor agonists for pain management
WO2004100947A2 (en) 2003-05-06 2004-11-25 Smithkline Beecham Corporation Novel chemical compounds
EP1677791A4 (en) 2003-10-31 2007-08-15 Takeda Pharmaceutical NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
GB0328295D0 (en) * 2003-12-05 2004-01-07 Muscagen Ltd Therapeutic compounds
PT1696931E (pt) * 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
BRPI0509524A (pt) * 2004-04-01 2007-09-18 Acadia Pharm Inc formas cristalinas de n-desmetilclozapina
KR20070034049A (ko) 2004-06-09 2007-03-27 글락소 그룹 리미티드 피롤로피리딘 유도체
WO2006019497A2 (en) 2004-06-17 2006-02-23 Neurocrine Biosciences, Inc. Sleep-inducing compounds and methods related thereto
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
JO2724B1 (en) * 2004-08-19 2013-09-15 افينتس فارماسوتيكالز انك 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
ES2349416T3 (es) * 2004-10-25 2011-01-03 Eli Lilly And Company Tienopiridinas como potenciadores alostéricos del receptor muscarínico m4.
JP2008521821A (ja) * 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
EP1863490A2 (en) * 2005-03-28 2007-12-12 Vertex Pharmaceuticals Incorporated Muscarinic modulators
US20060258691A1 (en) * 2005-05-13 2006-11-16 Joseph Barbosa Methods and compositions for improving cognition
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CA2619972A1 (en) * 2005-08-24 2007-03-01 Lexicon Pharmaceuticals, Inc. Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US8173672B2 (en) * 2008-03-21 2012-05-08 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
EP2408448A4 (en) * 2009-03-18 2012-09-19 Univ Leland Stanford Junior METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS
KR20120117905A (ko) 2010-01-28 2012-10-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 프로테아좀 활성을 향상시키는 조성물 및 방법
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
HUE044867T2 (hu) 2011-05-12 2019-11-28 Proteostasis Therapeutics Inc Proteosztázis szabályzók
HRP20181667T1 (hr) 2011-07-22 2018-12-14 Glaxosmithkline Llc Pripravak
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
EA026354B1 (ru) 2012-08-24 2017-03-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Пиразолопиримидиновые соединения
AU2013348217B2 (en) 2012-11-20 2016-10-06 Glaxosmithkline Llc Novel compounds
EA028480B1 (ru) 2012-11-20 2017-11-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
BR112015011439A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
AU2014240139A1 (en) 2013-03-15 2015-09-17 Acadia Pharmaceuticals Inc. Muscarinic agonists
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
JP6368270B2 (ja) * 2015-04-02 2018-08-01 株式会社エヌ・ティー・エイチ モニエロサイドａ及びその誘導体、又はそれを有効成分として含有する医薬用組成物、健康食品又は化粧品
US10730842B2 (en) * 2015-09-03 2020-08-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
EP3416639B1 (en) 2016-02-16 2022-06-08 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
GB201616839D0 (en) * 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
WO2019241467A1 (en) 2018-06-13 2019-12-19 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
US12065433B2 (en) 2018-10-24 2024-08-20 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
US11591323B2 (en) * 2019-03-06 2023-02-28 Barry university Muscarinic agonists as non-steroidal and non-opioid analgesics and methods of use thereof
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
WO2025000053A1 (en) * 2023-06-28 2025-01-02 Psylo Pty Ltd Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870085A (en) * 1984-08-17 1989-09-26 Bayer Aktiengesellschaft Tryptamine derivatives active on central nervous system
RU2095360C1 (ru) * 1990-10-15 1997-11-10 Пфайзер Инк. Производные индола, их оптические изомеры и фармацевтически приемлемые соли

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3412097A (en) * 1964-09-07 1968-11-19 Koninklijke Pharma Fab Nv Indole derivatives
BE669095A (https=) * 1964-09-07
US3417087A (en) * 1965-12-27 1968-12-17 Research Corp 3(aminopropionyl)benzothiophenes
US3855242A (en) * 1967-12-15 1974-12-17 Aspro Nicholas Ltd Benzo{8 b{9 thienyl-alkyl-guanidines
FR2305982A1 (fr) * 1975-04-03 1976-10-29 Innothera Lab Sa Nouvelles benzothienyl amino (propyl et butyl) cetones, leur procede de preparation et leur application en therapeutique
US4458075A (en) 1982-04-09 1984-07-03 Hoechst-Roussel Pharmaceuticals Inc. 6-Fluoro-3-[3-(1-heterocyclo)propyl]-1,2-benzisoxazoles
DE4039631A1 (de) 1990-12-12 1992-06-17 Troponwerke Gmbh & Co Kg Neuroprotektive kombination
US5143923B1 (en) 1991-04-29 1993-11-02 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
ES2187518T3 (es) * 1992-11-23 2003-06-16 Aventis Pharma Inc 3-(aminoalquilamino)-1-2-benzisoxazoles sustituidos y compuestos relacionados.
US5494908A (en) * 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
FR2735129B1 (fr) * 1995-06-07 1997-07-11 Adir Nouveaux derives de l'indole, de l'indazole et du benzisoxazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2751647B1 (fr) 1996-07-25 1998-09-11 Synthelabo Derives de benzimidazole, leurs preparations et leurs applications en therapeutique
US5900312A (en) 1996-11-08 1999-05-04 W. L. Gore & Associates, Inc. Integrated circuit chip package assembly
DE19725664A1 (de) 1997-06-18 1998-12-24 Merck Patent Gmbh 3-Benzylpiperidine
FR2803298A1 (fr) * 1999-12-30 2001-07-06 Adir Nouvelles urees lineaires ou cycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2804429B1 (fr) * 2000-01-31 2003-05-09 Adir Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR028385A1 (es) * 2000-04-28 2003-05-07 Acadia Pharm Inc Agonistas muscarinicos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870085A (en) * 1984-08-17 1989-09-26 Bayer Aktiengesellschaft Tryptamine derivatives active on central nervous system
RU2095360C1 (ru) * 1990-10-15 1997-11-10 Пфайзер Инк. Производные индола, их оптические изомеры и фармацевтически приемлемые соли

Also Published As

Publication number Publication date
WO2001083472A1 (en) 2001-11-08
TW200505900A (en) 2005-02-16
US20050113357A1 (en) 2005-05-26
AR028385A1 (es) 2003-05-07
EP1278741A1 (en) 2003-01-29
US20020037886A1 (en) 2002-03-28
NO20025115D0 (no) 2002-10-24
DE60109148D1 (de) 2005-04-07
ZA200208504B (en) 2004-01-22
CN1439002A (zh) 2003-08-27
CA2407594A1 (en) 2001-11-08
HK1058196A1 (en) 2004-05-07
ES2238437T3 (es) 2005-09-01
DE60109148T2 (de) 2006-01-05
NO20025115L (no) 2002-12-19
AU2001259190B2 (en) 2007-01-25
US7238713B2 (en) 2007-07-03
KR20030005306A (ko) 2003-01-17
US6627645B2 (en) 2003-09-30
NZ521978A (en) 2004-10-29
EP1278741B1 (en) 2005-03-02
CN1249051C (zh) 2006-04-05
CN1814596A (zh) 2006-08-09
JP2003531901A (ja) 2003-10-28
CN101016296A (zh) 2007-08-15
KR100901221B1 (ko) 2009-06-08
JP4119126B2 (ja) 2008-07-16
TWI310035B (en) 2009-05-21
BR0110420A (pt) 2003-07-01
MXPA02010550A (es) 2004-05-17
JP2008133297A (ja) 2008-06-12
US20070155795A1 (en) 2007-07-05
NO326106B1 (no) 2008-09-22
ATE290000T1 (de) 2005-03-15
KR20070086548A (ko) 2007-08-27
TWI306859B (en) 2009-03-01
TW200505901A (en) 2005-02-16
AU5919001A (en) 2001-11-12

Similar Documents

Publication Publication Date Title
RU2269523C2 (ru) Мускариновые агонисты
AU2001259190A1 (en) Muscarinic agonists
EP1499589B1 (fr) Derives de n-¬phenyl(piperidin-2-yl)methyl|benzamide, leur preparation et leur application en therapeutique
JPH08512299A (ja) ５ｈｔ▲下２ｃ▼アンタゴニストとしてのインドリン誘導体
JP2017519025A (ja) チオフェン−２−イル−ピリジン−２−イル−１ｈ−ピラゾール−４−カルボン酸誘導体、および可溶性グアニル酸シクラーゼ活性化剤としてのその使用
JPH07121943B2 (ja) ５−ｈｔ１アゴニストとしてのインドール誘導体
AU729786B2 (en) Carboxamides useful as 5-HT1F agonists
AU2010340745B2 (en) Sulfone compounds as 5-HT6 receptor ligands
CZ9302010A3 (en) DERIVATIVE OF 4-AMINO-1,3,4,5/TETRAHYDROBENZ(cd)INDOLE SUBSTITUTED IN POSITION 6 BY A HETEROCYCLIC GROUP, PROCESS OF ITS PREPARATION AND A PHARMACEUTICAL PREPARATION IN IT IS COMPRISED
JP4685861B2 (ja) ドーパミンアゴニストとしての３−ピペリジニルイソクロマン−５−オール
JPH09512025A (ja) ５ｈｔ▲下２ｃ▼および５ｈｔ▲下２ｂ▼アンタゴニストとしての三環式誘導体
WO2019225625A1 (ja) リードスルー誘導剤およびその医薬用途
WO1998042710A1 (fr) Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
EP1535912A1 (en) Muscarinic agonists
AU2007201832A1 (en) Muscarinic agonists
NZ533227A (en) Benzoisothiazole based compounds as muscarinic agents
CN118930552A (zh) 异苯并呋喃-1(3h)-酮类化合物及其制备方法、药物组合物和用途
HK1131977A (en) Indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
JPH11217377A (ja) 新規アルキルアミノ誘導体